Company Overview of Alvogen, Inc.
Alvogen, Inc. engages in the product development, contract manufacturing and research, and sale of generic and brand medicines, biosimilars, and OTC products. Its product portfolio comprises a range of molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology, and gastroenterology. The company focuses on niche generics, patches, controlled release, and narcotics in the form of solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments, and injectables; promotes and distributes various biosimilar products for indications across several therapeutic areas; provides contract manufacturing, product development, ...
10 Bloomfield Avenue
Pine Brook, NJ 07058
Founded in 2008
Key Executives for Alvogen, Inc.
Executive Chairman and Chief Executive Officer
Executive Vice President of Global Supply Chain
Chief Operating Officer and Member of Executive Board
Member of Executive Board and Chief Executive Officer of Alvogen America
President of Alvogen America
Compensation as of Fiscal Year 2015.
Alvogen, Inc. Key Developments
Alvogen, Inc. Announces Executive Changes
Oct 1 15
Alvogen announced that Kevin Bain, the company‘s Chief Financial Officer since 2009 will take on the role of Chief Financial Officer of Alvogen‘s biotech sister company, Alvotech and continue as EVP of Strategic Development at Alvogen. Alvogen also announced that Graham Baker will be appointed as the group‘s new Chief Financial Officer, effective 1 November 2015. Graham joins Alvogen from AstraZeneca, where he has spent the past 20 years of his career, most recently as Vice President of Finance for AstraZeneca’s international business. Graham will be responsible for all global finance and information services for Alvogen.
Alvogen Launches the First Generic Exelon® Patch in the United States
Sep 4 15
Alvogen has launched the first generic equivalent of Exelon® patch (rivastigmine transdermal system) in the United States. The product will be marketed by Alvogen in three strengths (4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours) with Alvogen being the first filer for the 13.3 mg/24 hours strength, making it eligible for 180 days of marketing exclusivity. Novartis’s Exelon® patch, delivered sales of approximately $400 million in the United States during 2014.
Alvogen Appoints Lisa Graver as President of Americas Region
Aug 5 15
Alvogen announced the appointment of Lisa Graver as president of Americas region effective immediately.
Similar Private Companies By Industry
Recent Private Companies Transactions